Odonate Therapeutics Inc (NASDAQ:ODT) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price objective of $45.00 for the company and are anticipating that the company will post ($1.08) EPS for the current quarter, according to Zacks. Zacks has also given Odonate Therapeutics an industry rank of 55 out of 255 based on the ratings given to its competitors.
ODT has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Odonate Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 12th. ValuEngine lowered shares of Odonate Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd.
A number of hedge funds have recently added to or reduced their stakes in ODT. Meeder Asset Management Inc. increased its holdings in Odonate Therapeutics by 198.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,574 shares of the company’s stock valued at $57,000 after buying an additional 1,047 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Odonate Therapeutics by 106.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,703 shares of the company’s stock valued at $63,000 after purchasing an additional 880 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Odonate Therapeutics by 109.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,351 shares of the company’s stock valued at $196,000 after purchasing an additional 2,800 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Odonate Therapeutics by 30.0% in the 3rd quarter. Rhumbline Advisers now owns 12,365 shares of the company’s stock valued at $322,000 after purchasing an additional 2,854 shares in the last quarter. Finally, Swiss National Bank acquired a new stake in shares of Odonate Therapeutics in the 2nd quarter valued at approximately $455,000. 98.18% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:ODT traded up $4.07 during mid-day trading on Tuesday, reaching $37.33. 124,311 shares of the company’s stock were exchanged, compared to its average volume of 91,891. Odonate Therapeutics has a one year low of $11.54 and a one year high of $43.75. The firm has a market capitalization of $1.06 billion, a PE ratio of -10.26 and a beta of 1.83. The business’s fifty day simple moving average is $29.66 and its two-hundred day simple moving average is $29.81.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Featured Story: Inverted Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.